Growth Stage

Making a Difference, Naturally.

Making a Difference, Naturally.


Raised to Date: Raised: $15,595

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common



SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Consumer Products, Goods & Services

Tech Sector


Distribution Model




Capital Intensity



Canoga Park, California

Business Type


Med-X, with a pre-money valuation of $88.5 million, is raising funds on TruCrowd. The company has developed many all-natural and plant-based brands that are replacing chemicals to solve the everyday issues of people. The products are sold through major retail and healthcare distributors. The flagship product lines of Med-X include Nature-Cide and Thermal-Aid. Med-X is led by Dr. David Toomey and Matthew Mills and was founded in 2014. The proceeds of the current crowdfunding campaign, with a minimum raise of $10,000 and a maximum raise of $1,070,000, will be used for future growth and expansion. Med-X has a high demand and is known for its all-natural solutions in the fields of pest control and pharmaceuticals.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 05/24/2020
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Med-X 11/08/2023 Dalmore Group $102,217,405 $3,936,422 Equity - Common Funded RegA+
Med-X 05/22/2023 PicMii $43,211,544 $0 Equity - Common Not Funded RegCF
Med-X 09/09/2021 truCrowd $88,552,772 $15,595 Equity - Common Funded RegCF
Med-X 06/26/2019 StartEngine - $7,000,471 Equity - Common Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article


The Med-X team has been selected as an “Underweighted Deal” by KingsCrowd. If you have questions regarding our deal diligence and selection methodology, please reach out to

Next Section: Problem


Today we are exposed to greater levels of synthetic chemicals than we were merely one human lifespan ago. In well under a century, our rate of chemical production has increased 400-fold. The number of new chemicals introduced each year is in the thousands. Out of the 80,000+ chemicals registered for commercial use in the US, a shockingly low one-third of one percent have been safety-tested by government agencies. 


This leaves society in a state of complete dependency on potentially dangerous artificial chemicals. This dependency extends from industrial uses to ingredients in pharmaceutical products and even our food.

Next Section: Solution


Med-X is a consumer product company that markets a diversified catalog of proprietary, wellness-focused products made from natural, plant-based ingredients. 


Its two flagship product lines are:


  • Nature-Cide, a collection of naturally derived pest control, repellent and insecticide formulations.


  • Thermal-Aid, a suite of heating/cooling packs for management of pain or swelling that feature specialized varieties of corn as the filler material that’s heated or cooled prior to application on the body.


The two product lines listed above can rightly be regarded as the company’s premier divisions. They each have meaningful distribution partnerships in place (Nature-Cide through vendors such as Target Specialty Products and Univar and Thermal-Aid through outlets such as Cardinal Health).


The company also sells homeopathic pain relief creams through its Malibu Brands line as well as aromatherapy shower sprays under the Home Spa marque. Finally, Med-X also maintains two non-product offering lines: a marijuana-focused periodical and a business news site

Next Section: Other

The Team

Med-X’s current CEO, Dr. David Toomey, spent much of his career as a family physician and Medical Director in the hospice industry.


Many members of the Med-X team – likely including the company’s President & Chief Operating Officer; its Chief Financial Officer, and its Chief Media Officer – appear to have joined Med-X by way of its 2018 merger with consumer products vendor Pacific Shore Holdings


In fact, prior to that time, Med-X was a self-described cannabis cultivation company. However, the company discovered that its natural pesticide products, although originally intended mainly for application to their own cannabis crops, actually had commercial potential in several industries unrelated to cannabis.

Next Section: Other

Growth Plan

Med-X asserts that the markets for its two core product areas – namely, pest control and pain management – have each been enjoying healthy year-over-year growth. Such assertions appear to be borne out by independent analyses of the pest control and pain management markets, respectively. 


Within this environment of growth, the company anticipates that it will be able to expand its Nature-Cide sales footprint across an increasing number of commercial client types. Med-X plans to sell to janitorial companies, property managers, and landscapers while also promoting a line of retail-focused Nature-Cide products for direct consumer purchase through big-box stores. 


Meanwhile, the Med-X team aspires to pull off a similarly broad expansion campaign for its Thermal-Aid products, by promoting them across a progressively broad set of retail vendors, over-the-counter pharmacies, and healthcare enterprises.

Next Section: Other

What We Think

Unfocused Product Portfolio Strategy: Although some major consumer product companies (e.g. Procter & Gamble) have found tremendous success in taking diversified product catalogs to market, Med-X has struggled to define or articulate a coherent logic for the jumble of product lines that it has assembled. The company’s attempt to frame its corn-filled heating/cooling pads sold via its Thermal-Aid brand, as being “all-natural” in the same sense that their pesticides are free of artificial chemicals, strains credibility. 


Meanwhile, the company’s product strategy for its Malibu Brands homeopathic pain relief creams is even more muddled – as the company’s own materials state that they seek to position Malibu Brands to compete with cannabis and CBD-based pain relief products… Yet also declare that they wish to pursue their own cannabis formulations. 


As for the company’s informational lines of business (its marijuana periodical and its business news site) – it’s not evident that these digital properties have solid prospects for driving interest in the company’s core products. Nor is it clear that they stand to generate meaningful revenues in their own right. 


Wildly Overvalued Deal Terms: The company’s offered pre-money valuation of $88M is outrageously high. 


While the Med-X team understandably aspires to emulate the success of breakout natural product companies such as Seventh Generation (sold to Unilever for a reported $600M) or The Wonderful Company (privately held with a multi-billion-dollar valuation), the fact remains that these success stories grew to point where they were generating hundreds of millions, or even billions of dollars in annual revenues, thereby justifying their lofty valuations. The $88M valuation offered in the current deal would be more appropriate for a company growing at breakneck speed and undertaking something like a Series B funding round. This nearly nine-figure valuation is not even close to justified for a company such as Med-X that has been around since 2014 – but that, according to its Form C, only managed to generate $646K and $801K in revenues for 2018 and 2019, respectively. 


Prospective investors should also be aware that Med-X had one of its previous equity crowdfunding campaigns suspended, due to the company’s failure to submit required filings to the SEC in a timely fashion.


Company Continues to Generate Massive Losses: Med-X’s messy product portfolio and high sought valuation, as described above, might have been easier to stomach, if the company was delivering solid earnings or growing rapidly while keeping the level of corporate losses within a reasonable range, relative to revenues. Unfortunately, this has not been the case with the company’s recent performance. Med-X generated a net loss of $3.4M in 2018 – followed by an even bigger loss in excess of $4M in 2019. These widening loss figures, which utterly dwarf the company’s revenue amounts, make it impossible to regard the Med-X investment opportunity with anything other than skepticism.

Next Section: Rating


From an ethical consumption perspective, the efforts of companies such as Med-X to introduce all-natural, plant-based products into the market, and thereby wean society off its dependency on petrochemical-derived products, should be applauded. 


However, from the standpoint of assessing the Med-X deal as an investment opportunity, it simply doesn’t appear that the company has yet hit upon a formula for business success. None of Med-X’s (individually quite distinctive) product lines appear to be currently capable of generating even meaningful levels of gross profit, much less positive net profits. 


And there’s no clear logic for why any of those individual product lines would be expected to complement one another. This makes it unlikely that Med-X will be perceived any time soon as a trusted comprehensive provider of a consumer’s entire list of household product needs – in the way that all-natural powerhouses such as Seventh Generation (or even incumbent brands such as Procter & Gamble) are viewed by their loyal fans. 


Lastly, the fact that Med-X is holding out for a sky-high valuation that’s an order of magnitude above prevailing market valuations is itself another red flag that the Med-X team is not applying good judgment or a sense of realism to its business or fundraising strategies.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Med-X on TruCrowd
Platform: truCrowd
Security Type: Equity - Common
Valuation: $88,552,772
Price per Share: $0.80

Follow company

Follow Med-X on TruCrowd

Buy Med-X's Deal Report

Warning: according to the close date for this deal, Med-X may no longer be accepting investments.

Med-X Deal Report

Get KingsCrowd’s comprehensive report on Med-X including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Med-X is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the Med-X deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge